Sjögren’s Syndrome (SS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Sjögren’s Syndrome (SS) Market Outlook

Thelansis’s “Sjögren’s Syndrome (SS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sjögren’s Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sjögren’s Syndrome (SS) Overview

Sjögren syndrome (SS) is a gradually progressing autoimmune disorder with various organ-specific and systemic symptoms. In SS patients, B-cell activation is consistently observed, leading to the infiltration of B and T cells into target organs, resulting in damage. The typical SS patient, most commonly perimenopausal women, experiences reduced lacrimal and salivary gland function symptoms. Common manifestations include dry mouth (xerostomia), dry eyes (keratoconjunctivitis sicca), and enlargement of the parotid glands. The oral dryness experienced by SS patients can significantly impact their quality of life, interfering with basic daily activities like eating, speaking, and sleeping. The reduction in salivary volume also reduces saliva's natural antibacterial properties, increasing the risk of infections, tooth decay, and periodontal disease. SS patients often complain of ocular discomfort, including itching, grittiness, soreness, and dryness, despite the outward appearance of normal eyes. The reduced tear secretion can lead to chronic irritation and damage to the corneal and bulbar conjunctival epithelium (keratoconjunctivitis sicca). Salivary gland swelling, initially unilateral but often becoming bilateral, can be either chronic or episodic. Sjögren syndrome can occur independently as primary SS or in conjunction with systemic autoimmune rheumatic diseases, referred to as secondary SS. Because SS symptoms may not manifest simultaneously, medical professionals, including physicians and dentists, may treat individual symptoms without recognizing the underlying systemic disease. The differential diagnosis of SS involves considering conditions and medications that can cause symptoms such as keratoconjunctivitis sicca, xerostomia, and parotid gland enlargement. Two FDA-approved drugs, Salagen (pilocarpine) and Evoxac (cevimeline), can increase saliva production and treat dry mouth in SS. The prevalence of SS varies significantly across different reports, with changes of up to tenfold noted between countries and within the same country.

• Reported prevalence rates range from 0.1% to 4.8%. Worldwide, SS prevalence varies, with 320 cases in North America and 200 to 3,000 cases per 100,000 individuals in Northern and Southern Europe, respectively.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: